Finally, we reaffirmed our full-year guidance for 2022 and remain confident that our internal initiatives coupled with the strong market backdrop provide us with a clear path to achieve Subsea EBITDA of more than $1 billion by 2025.”
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis.
